Amgen Inc.
As of Fiscal Year 2025 (ended December 31, 2025)
Key KPIs at a Glance
| Metric | Value |
|---|---|
| Total revenue (FY2025) | $36.75 billion, up 10% year-over-year (from $33.42 billion in FY2024) |
| Total product sales (FY2025) | $35.15 billion, up 10% year-over-year |
| Net income, GAAP (FY2025) | $7.71 billion, up 88% from $4.09 billion in FY2024 |
| Diluted EPS, GAAP (FY2025) | $14.23, up 88% year-over-year |
| Diluted EPS, non-GAAP (FY2025) | $21.84, up 10% year-over-year |
| Operating income, GAAP (FY2025) | $9.08 billion (~24.7% operating margin), up from $7.26 billion in FY2024 |
| Research and development expense (FY2025) | $7.27 billion, up 22% year-over-year |
| SG&A expense (FY2025) | $7.05 billion, roughly flat year-over-year |
| Free cash flow (FY2025) | ~$8.1 billion |
| U.S. vs. rest-of-world product sales (FY2025) | $25.66 billion U.S. (73%) vs. $9.49 billion rest-of-world (27%) |
| Employees (as of December 31, 2025) | approximately 31,500 (third-party aggregation of Amgen's FY2025 10-K) |
| FY2026 revenue guidance | $37.0-$38.4 billion (company guidance issued with FY2025 results) |
Sources: Total revenue, product-line revenue, net income, operating income, R&D/SG&A expense and EPS are from Amgen's Q4/FY2025 earnings release (reported February 3, 2026, covering the twelve months ended December 31, 2025) and the related SEC filing. Amgen operates as a single reportable segment and does not disclose operating income or net income by product, so no operating-income breakdown is shown. The 'Other products & biosimilars' slice consolidates roughly two dozen smaller product lines (including Uplizna, Tavneos, Vectibix, Lumakras/Lumykras, Imdelltra, Mvasi, Parsabiv, Neulasta, the Ultra-Rare franchise, and legacy biosimilars/mature brands) that Amgen reports individually but which are too numerous to chart separately; 'Other revenues' is royalty, collaboration and other non-product revenue. Employee headcount is from third-party aggregation of Amgen's FY2025 10-K (StockAnalysis.com). The EVENITY bone-builder market-share figure is Amgen management's own statement on the Q4 2025 earnings call (February 3, 2026), not an independent third-party estimate; the remaining ~40% is not broken out by competitor.